TPST Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.8M
-46.2%
5.3M
-81.1%
27.7M
+579.9%
4.1M
+13.3%
3.6M
R&D
207.0K
-88.6%
1.8M
-91.8%
22.3M
+4036.2%
539.0K
-5.4%
570.0K
SG&A
2.6M
-23.8%
3.4M
-36.8%
5.4M
+53.3%
3.5M
+16.9%
3.0M
Operating Income
-2823000
+46.2%
-5250000
+81.1%
-27719000
-579.9%
-4077000
-13.3%
-3597000
EBITDA
-2767000
+46.7%
-5190000
+81.2%
-27659000
-589.4%
-4012000
-13.6%
-3531000
Net Income
-2823000
+46.2%
-5244000
+81.1%
-27696000
-588.8%
-4021000
-11.8%
-3597000
EPS (Basic)
$-0.21
+38.2%
$-0.34
+86.6%
$-2.53
-208.5%
$-0.82
-3.8%
$-0.79
EPS (Diluted)
$-0.21
+38.2%
$-0.34
+86.6%
$-2.53
-208.5%
$-0.82
-3.8%
$-0.79
Shares (Diluted)
16.9M
+11.1%
15.2M
+39.3%
10.9M
+122.3%
4.9M
+10.8%
4.4M
Tempest Therapeutics (TPST) — Financials